About: Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.40 (-0.11%)
PTN NASDAQ Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc. Common Stock share price
PTN price activity
Último preço
$ 9,400
Variação (24h)
-0,01 USD (-0,11%)
Volume
6.34K
Volume (média 4 sem.)
-
Abertura
$ 9,87
Variação do dia
$ 9,16 - $ 9,87
Fechamento anterior
$ 9,41
Último negócio
07 Oct, 4:52 pm GMT+0
Atrasado
07 Oct, 4:52 pm GMT+0
PTN price performance
Atrasado
07 Oct, 4:52 pm GMT+0
quote.marketSignals